SAN MATEO, Calif., Jan. 7 /PRNewswire-FirstCall/ -- NeurogesX, Inc. , a biopharmaceutical company focused on developing and commercializing novel pain management therapies, announced today that Anthony DiTonno, President and Chief Executive Officer, is scheduled to present at the 28th Annual J.P. Morgan Healthcare Conference, to be held January 11-14, 2009 at the Westin St. Francis Hotel in San Francisco, California.
The presentation will be webcast live and can be accessed by visiting the investor relations section of NeurogesX' website at www.neurogesx.com. The webcasts will be archived for 90 days.
The Company's lead product, Qutenza(R) (capsaicin) 8% patch, is a dermal delivery system containing a prescription strength of capsaicin that is currently approved in the United States and the European Union. NeurogesX expects to launch Qutenza in United States in the first half of 2010 for patients with postherpetic neuralgia (PHN). In Europe, Qutenza will be marketed by Astellas Pharma Europe Ltd., (Astellas), the European subsidiary of Tokyo-based Astellas Pharma Inc.
The Company's early stage product pipeline includes pre-clinical compounds which are prodrugs of acetaminophen and various opioids. The Company has evaluated these compounds in vitro and in vivo.
CONTACT: Stephen Ghiglieri, Chief Financial Officer, NeurogesX, Inc.,
+1-650-358-3310; or Sara Pellegrino (investors), +1-646-536-7002,
spellegrino@theruthgroup.com, or Jason Rando (media), +1-646-536-7025,
jrando@theruthgroup.com, both of The Ruth Group
Web site: http://www.neurogesx.com/
